Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent:a case-control study

Table 1 Baseline Characteristics among men of African Descent from the US & Jamaica

Characteristics	Cases	Controls	p value^†
Number of Participants, n	279	535	---
Age at enrollment (yrs), Median (range)	67 (45–91)	53 (27–89)	<0.0001
Family History of Prostate Cancer, n (%)
Yes	35 (16.1)	21 (12.5)	0.316
No	182 (83.9)	147 (87.5)
Missing	62 (22.2)	367 (68.6)
PSA (ng/ml), median	11.7 (0.01-10,000)	0.9 (0.0-4.0)	<0.0001
PSA (ng/ml), n (%)
< 4	37 (13.8)	517 (99.8)	<0.0001
≥ 4	231 (86.2)	1 (0.2)
Missing	11 (0.04)	17 (0.03)
Gleason Score, n (%)
4	12 (5.6)
5	14 (6.5)
6	74 (34.2)
7	70 (32.4)
8	18 (8.3)
9	22 (10.2)
10	6 (2.8)
Missing	63 (22.6)
Global WAA, mean (SD)	0.79 (0.25-0.94)	0.767 (0.25-0.95)	0.107

Abbreviations: PSA, prostate specific antigen; WAA, West African Ancestry; ^†Differences in family history or PSA frequencies between cases and controls were tested by a Chi-square test of homogeneity; differences in median age (yrs) and Global West African Ancestry between cases and controls were tested using the Wilcoxon sum Rank test.

ISSN: 1897-4287